Company intelligence / Profile preview
Nanjing Miracle Biotechnology
Nanjing, Jiangsu, Chinanjmiracle.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
Nanjing Miracle Biotechnology is an industry-leading cell therapy innovator dedicated to developing universal CAR-T (UCAR-T) treatments for solid tumors, hematological cancers, and autoimmune diseases. Founded in 2023 by Dr. Guo Zhigang, the company leverages its proprietary robusT® core technology platform to overcome the traditional challenges of autologous CAR-T therapies, aiming to deliver highly effective, accessible, and affordable cell therapy products. Its lead candidate, CHT-101, is an allogeneic CD70-targeted CAR-T cell therapy currently in Phase 1 clinical development for indications such as high-grade glioma, cutaneous T-cell lymphoma, and systemic lupus erythematosus. The company is headquartered in the Jiangsu Life Science and Technology Innovation Park in Nanjing, China.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- CAR-T cell therapyCell therapyGene therapyBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Tianjin Medical University Cancer Institute and HospitalZhejiang UniversityNanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Beyond the preview
Go deeper on Nanjing Miracle Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Miracle Biotechnology.